Overview

An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization

Status:
Recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The first stage of this study will evaluates the tolerability of different concentrations of Conbercept eye drop to patients with corneal neovascularization. The second stage of this study will evaluate the effectiveness of conbercept eye drop initially.

Phase:

Phase 1

Details

Lead Sponsor:

Chengdu Kanghong Biotech Co., Ltd.

Treatments:

Ophthalmic Solutions